Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting

Imaging assessment in Neuro-Oncology Presented By Susan Chang at 2014 ASCO Annual Meeting

Limitation: Early Pseudo-Progression after radiochemotherapy Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 4 Presented By Susan Chang at 2014 ASCO Annual Meeting

Limitation- Determination of enhancing and non- enhancing tumor burden post antiangiogenic treatment Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 6 Presented By Susan Chang at 2014 ASCO Annual Meeting

# 2007 Validation of RANO Criteria: Contribution of T2/FLAIR Assessment in Patients with Recurrent Glioblastoma Treated with Bevacizumab- Huang et al Presented By Susan Chang at 2014 ASCO Annual Meeting

Assessment of RANO Presented By Susan Chang at 2014 ASCO Annual Meeting

RANO-Endpoints and Trial Design Presented By Susan Chang at 2014 ASCO Annual Meeting

# Final Results of APG101_CD_002: APG101 + Reirradiation versus Reirradiation in the Treatment of Patients with Progressive Glioblastoma: Platten et al Presented By Susan Chang at 2014 ASCO Annual Meeting

Results Presented By Susan Chang at 2014 ASCO Annual Meeting

APG101_CD_002: Novel Biomarker for OS Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 13 Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 14 Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 15 Presented By Susan Chang at 2014 ASCO Annual Meeting

Results for ICT-107 Ph II Presented By Susan Chang at 2014 ASCO Annual Meeting

Authors conclusions/Comments Presented By Susan Chang at 2014 ASCO Annual Meeting

Authors conclusions/Comments Presented By Susan Chang at 2014 ASCO Annual Meeting

What “success” in a phase II trial warrants phase III evaluation? Presented By Susan Chang at 2014 ASCO Annual Meeting

Future RANO efforts Presented By Susan Chang at 2014 ASCO Annual Meeting

Acknowledgements Presented By Susan Chang at 2014 ASCO Annual Meeting